Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes
Abstract Cancers harboring mutations in the Kirsten rat sarcoma homolog (KRAS) gene have been associated with poor prognosis and lack of targeted therapies. KRAS mutations occur in approximately one in four patients diagnosed with non-small cell lung cancer (NSCLC) with KRAS G12C mutations harbored...
Saved in:
Main Authors: | Gabriela Palma, Faisal Khurshid, Kevin Lu, Brian Woodward, Hatim Husain |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/4bf6f3db8dc04db6a4984258c49d0174 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
by: Shaima’a Hamarsheh, et al.
Published: (2020) -
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
by: Alejandro Ruiz-Patiño, et al.
Published: (2022) -
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
by: Tatu Pantsar
Published: (2020) -
Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
by: Soonsil Hyun, et al.
Published: (2021) -
Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation
by: Yoshihito Kano, et al.
Published: (2019)